Clinical Trial Update: MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma [Phase 2]

View source ↗

Summary

The Phase 2 MagnetisMM-4 umbrella study evaluating elranatamab in combination with anti-cancer therapies for multiple myeloma was terminated, and results have b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Elranatamab (elranatamab)

Snippet

Sponsor: Pfizer | Conditions: Multiple Myeloma | Phase 2 | Status: TERMINATED | Results posted: 2026-02-23